3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
24
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Multiple Myeloma
17
Recurrence
9
Lymphoma, Large B-Cell, Diffuse
7
Endometrial Neoplasms
4
Lymphoma, T-Cell, Peripheral
3
Glioblastoma
3
Colorectal Neoplasms
3
Sarcoma
2
Primary Myelofibrosis
2
Neoplasms
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Carcinoma, Squamous Cell
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Richter's Transformation
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Azacitidine
142
Cytarabine
109
venetoclax
94
fludarabine
35
Daunorubicin
34
Decitabine
32
Idarubicin
26
gilteritinib
24
Cyclophosphamide
21
quizartinib
15
midostaurin
15
Mitoxantrone
14
Etoposide
14
Granulocyte Colony-Stimulating Factor
12
Gemtuzumab
11
CPX-351
11
decitabine and cedazuridine drug combination
10
Drug Therapy
10
cc-486
9
Filgrastim
9
Clofarabine
9
ivosidenib
8
Injections
8
Dexamethasone
8
pevonedistat
7
fludarabine phosphate
7
AP 1903 reagent
7
posaconazole
6
magrolimab
6
glasdegib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid, Acute
×
selinexor
×
Clear all
NCT02088541
2023-01-26
SOPRA
Karyopharm Therapeutics Inc
Phase 2
Completed
317 enrolled
25 charts